Kasvu develops first and best-in-class small molecule neuroplastogens for diseases where neuronal connectivity is altered
Kasvu Therapeutics has raised $34.2M in total funding. The most recent round was Series A. The last funding was announced in September 2026.
Kasvu Therapeutics's investors include Tesi, Innovestor, Hadean Ventures, Nordic Science Investments, Stephen Industries.
Kasvu Therapeutics is headquartered in Helsinki, Finland.
Kasvu develops first and best-in-class small molecule neuroplastogens for diseases where neuronal connectivity is altered
Kasvu Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kasvu Therapeutics — Funding & Investors." VCBacked, September 24, 2026, https://www.vcbacked.co/company/kasvu-therapeutics. Accessed October 4, 2026.
VCBacked. (2026). Kasvu Therapeutics — Funding & Investors. Retrieved October 4, 2026, from https://www.vcbacked.co/company/kasvu-therapeutics
{{cite web |title=Kasvu Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/kasvu-therapeutics |website=VCBacked |access-date=October 4, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated